Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02675231
Title A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company

Her2-receptor positive breast cancer



Abemaciclib + Trastuzumab

Abemaciclib + Fulvestrant + Trastuzumab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.